Go Pro

Andrew Fein Analyst Performance

MD/Senior Analyst at HC Wainwright

Andrew Fein is a stock analyst at HC Wainwright focused in the medical sector, covering 63 publicly traded companies. Over the past year, Andrew Fein has issued 13 stock ratings, including buy and hold recommendations. While full access to Andrew Fein's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew Fein's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
306 Last 11 Years
Buy Recommendations
93.98% 281 Buy Ratings
Companies Covered
63 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy94.0%281 ratings
Hold6.0%18 ratings
Sell0.0%0 ratings

Out of 299 total stock ratings issued by Andrew Fein at HC Wainwright, the majority (94.0%) have been Buy recommendations, followed by 6.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.1% of companies on NASDAQ
58 companies
NYSEAMERICAN
3.2% of companies on NYSEAMERICAN
2 companies
TSE
1.6% of companies on TSE
1 company
NYSE
1.6% of companies on NYSE
1 company
OTCMKTS
1.6% of companies on OTCMKTS
1 company

Andrew Fein, an analyst at HC Wainwright, currently covers 63 companies listed on NASDAQ, NYSEAMERICAN, TSE, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
61 companies
96.8%
Basic Materials
1 company
1.6%
Aerospace
1 company
1.6%

Andrew Fein of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Basic Materials and Aerospace companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
39 companies
61.9%
MED - DRUGS
12 companies
19.0%
PHARMACEUTICAL PREPARATIONS
8 companies
12.7%
BIOTECHNOLOGY
2 companies
3.2%
MISCELLANEOUS CHEMICAL PRODUCTS
1 company
1.6%
AEROSP/DEF EQ
1 company
1.6%

About Andrew Fein

Mr. Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart. Mr. Fein has received numerous honorable mentions from the Institutional Investor All-America Research poll. Mr. Fein’s educational background includes a Bachelor of Arts degree from Yale University.
Follow on LinkedIn

Andrew Fein's Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2/17/2026Set Price Target$491.47$591.00
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
1/9/2026Boost Price Target$15.82$37.00Buy
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
12/18/2025Set Price Target$20.80$40.00
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
11/7/2025Boost Price Target$12.36$20.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
10/30/2025Boost Price Target$450.79$525.00Buy
Alector, Inc. stock logo
ALEC
Alector
10/22/2025Lower Price Target$1.52$5.00Buy
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
10/10/2025Reiterated Rating$54.08$54.00Neutral
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
9/5/2025Boost Price Target$380.47$500.00Buy
Biogen Inc. stock logo
BIIB
Biogen
8/1/2025Boost Price Target$128.00$194.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
7/31/2025Set Price Target$281.95$400.00Buy
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7/29/2025Upgrade$7.65$12.00Buy
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
7/8/2025Boost Price Target$15.06$27.00Buy
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6/30/2025Upgrade$4.90$23.00Buy
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
6/26/2025Reiterated Rating$46.47$60.00Buy
Biogen Inc. stock logo
BIIB
Biogen
6/26/2025Reiterated Rating$127.31$187.00Buy
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
6/26/2025Reiterated Rating$22.50$32.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6/23/2025Reiterated Rating$440.87$550.00Buy
Insmed, Inc. stock logo
INSM
Insmed
6/11/2025Boost Price Target$90.93$120.00Buy
Arvinas, Inc. stock logo
ARVN
Arvinas
6/2/2025Set Price Target$7.51$24.00
Savara Inc. stock logo
SVRA
Savara
5/29/2025Downgrade$2.14$2.00Neutral
PepGen, Inc. stock logo
PEPG
PepGen
5/29/2025Lower Price Target$1.58$8.00Buy
Liquidia Corporation stock logo
LQDA
Liquidia
5/28/2025Boost Price Target$15.60$35.00Buy
Prothena Corporation plc stock logo
PRTA
Prothena
5/27/2025Lower Price Target$6.58$14.00Buy
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
5/27/2025Downgrade$7.89$8.00Neutral
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
5/19/2025Boost Price Target$22.26$32.00Buy
Annexon, Inc. stock logo
ANNX
Annexon
5/14/2025Lower Price Target$1.75$14.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
5/14/2025Lower Price Target$8.90$35.00Buy
Insmed, Inc. stock logo
INSM
Insmed
5/12/2025Reiterated Rating$65.08$90.00Buy
Liquidia Corporation stock logo
LQDA
Liquidia
5/12/2025Reiterated Rating$15.32$29.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
5/9/2025Lower Price Target$11.32$38.00Buy
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
5/9/2025Boost Price Target$4.65$16.00Buy
PepGen, Inc. stock logo
PEPG
PepGen
5/9/2025Lower Price Target$1.58$14.00Buy
Prothena Corporation plc stock logo
PRTA
Prothena
5/9/2025Lower Price Target$7.43$30.00Buy
Alector, Inc. stock logo
ALEC
Alector
5/9/2025Boost Price Target$1.11$10.00Buy
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
5/8/2025Lower Price Target$13.68$25.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
5/7/2025Lower Price Target$13.55$32.00Buy
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
5/6/2025Reiterated Rating$11.03$30.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
5/5/2025Reiterated Rating$294.60$425.00Buy
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
5/5/2025Boost Price Target$8.95$16.00Buy
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
5/2/2025Reiterated Rating$99.25$135.00Buy
CODE RED: AI Meltdown Imminent? (Ad)

After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel

See the five simple steps to prepare before it's too late
Biogen Inc. stock logo
BIIB
Biogen
5/2/2025Lower Price Target$121.39$187.00Buy
Arvinas, Inc. stock logo
ARVN
Arvinas
5/2/2025Lower Price Target$7.08$24.00Buy
AC Immune stock logo
ACIU
AC Immune
5/1/2025Lower Price Target$1.73$12.00Buy
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4/22/2025Lower Price Target$100.68$168.00Buy
Insmed, Inc. stock logo
INSM
Insmed
4/22/2025Reiterated Rating$69.51$90.00Buy
Arvinas, Inc. stock logo
ARVN
Arvinas
4/7/2025Reiterated Rating$6.56$81.00Buy
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
4/4/2025Lower Price Target$0.73$7.00Buy
AC Immune stock logo
ACIU
AC Immune
4/3/2025Reiterated Rating$1.88$16.00Buy
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
4/1/2025Reiterated Rating$10.19$40.00Buy
Savara Inc. stock logo
SVRA
Savara
3/28/2025Reiterated Rating$2.78$6.00Buy
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3/28/2025Lower Price Target$1.23$11.00Buy
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
3/27/2025Reiterated Rating$1.76$10.00Buy
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
3/26/2025Reiterated Rating$9.75$22.00Buy
Liquidia Corporation stock logo
LQDA
Liquidia
3/20/2025Reiterated Rating$14.92$29.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/19/2025Reiterated Rating$8.87$47.00Buy
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
3/17/2025Reiterated Rating$1.77$10.00Buy
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3/17/2025Reiterated Rating$8.10$20.00Neutral
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/17/2025Reiterated Rating$12.23$46.00Buy
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3/14/2025Lower Price Target$2.11$14.00Buy
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3/14/2025Reiterated Rating$12.25$20.00Buy
AC Immune stock logo
ACIU
AC Immune
3/14/2025Reiterated Rating$2.30$16.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3/14/2025Boost Price Target$1.74$12.00Buy
Arvinas, Inc. stock logo
ARVN
Arvinas
3/11/2025Reiterated Rating$8.49$81.00Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3/7/2025Reiterated Rating$4.50$13.00Buy
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3/6/2025Initiated Coverage$3.06$8.00Buy
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3/6/2025Reiterated Rating$3.63$23.00Buy
Kamada Ltd. stock logo
KMDA
Kamada
3/6/2025Reiterated Rating$7.10$11.00Buy
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3/6/2025Reiterated Rating$1.92$15.00Buy
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3/5/2025Reiterated Rating$3.01$12.00Buy
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
3/5/2025Reiterated Rating$11.23$22.00Buy
Merus N.V. stock logo
MRUS
Merus
3/3/2025Reiterated Rating$47.09$85.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2/28/2025Lower Price Target$13.17$46.00Buy
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2/28/2025Boost Price Target$29.98$60.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
2/28/2025Boost Price Target$18.60$87.00Buy
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
2/28/2025Reiterated Rating$21.83$35.00Buy
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2/27/2025Lower Price Target$10.94$40.00Buy
Alector, Inc. stock logo
ALEC
Alector
2/27/2025Reiterated Rating$1.72$7.00Buy
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2/27/2025Reiterated Rating$18.96$27.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2/27/2025Reiterated Rating$318.89$425.00Buy
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2/25/2025Reiterated Rating$8.29$30.00Buy
PepGen, Inc. stock logo
PEPG
PepGen
2/24/2025Reiterated Rating$2.81$16.00Buy
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2/21/2025Reiterated Rating$116.11$185.00Buy
Insmed, Inc. stock logo
INSM
Insmed
2/21/2025Reiterated Rating$83.61$90.00Buy
Prothena Corporation plc stock logo
PRTA
Prothena
2/21/2025Reiterated Rating$15.25$48.00Buy
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
2/18/2025Reiterated Rating$8.51$75.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
2/18/2025Boost Price Target$9.74$47.00Buy
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2/14/2025Reiterated Rating$95.19$135.00Buy
Biogen Inc. stock logo
BIIB
Biogen
2/13/2025Lower Price Target$133.43$241.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2/11/2025Reiterated Rating$469.97$550.00Buy
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
2/10/2025Reiterated Rating$10.15$75.00Buy
Trump's gold order: the announcement they won't put on the front page (Ad)

On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel

Request the free guide in 30 seconds and get positioned now
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2/7/2025Lower Price Target$150.51$185.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
1/31/2025Boost Price Target$438.40$550.00Buy
PepGen, Inc. stock logo
PEPG
PepGen
1/30/2025Lower Price Target$1.84$16.00Buy
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
1/29/2025Lower Price Target$1.98$10.00Buy
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
1/23/2025Reiterated Rating$2.51$17.00Buy
Kamada Ltd. stock logo
KMDA
Kamada
1/10/2025Reiterated Rating$7.32$11.00Buy
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
1/10/2025Boost Price Target$22.80$35.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
1/10/2025Reiterated Rating$30.24$75.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
1/10/2025Reiterated Rating$15.68$55.00Buy
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10/18/2024Reiterated Rating$3.92$8.00Buy